HDM2024 Phase 1 Trial, Advanced Solid Tumors
ClinicalTrials.gov Studies
Summary
NIH registered a Phase 1 clinical trial (NCT07539285) for HDM2024, an investigational drug, in participants with advanced solid tumors. The trial will evaluate drug safety, tolerability, and antitumor activity. Participants receive the study drug once every three weeks, with imaging-based efficacy assessments every six weeks.
“The goal of this clinical trial is to learn if the study drug can work in advanced cancer patients”
What changed
NIH registered a new Phase 1 clinical trial for HDM2024 in participants with advanced solid tumors. The trial will assess safety, tolerability, and antitumor activity of the study drug administered once every three weeks.
This is an informational clinical trial registration that does not create compliance obligations. Pharmaceutical companies conducting Phase 1 oncology trials and clinical investigators should monitor ClinicalTrials.gov for updates as the trial progresses through enrollment and data collection phases.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study of HDM2024 in Participants With Advanced Solid Tumors
Phase 1 NCT07539285 Kind: PHASE1 Apr 20, 2026
Abstract
The goal of this clinical trial is to learn if the study drug can work in advanced cancer patients. The main questions it aims to answer are:
- Is the drug safe and tolerable ?
- Does the drug exhibit antitumor activity ?
Participants will receive the study drug once every three weeks, and imaging-based efficacy assessments will be performed every six weeks.
Conditions: Advanced Solid Tumors
Interventions: HDM2024
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.